SynthesisBMC women's health2020
Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.
Synthesis in BMC women's health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05341817 (The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy: a Randomized, Non-inferiority Trial
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Pooled it
- Medical methods for first trimester abortion.The Cochrane database of systematic reviews · 2022Pooled it
- Examining the association between prior medical mistreatment and interest in and support for over-the-counter medication abortion among people seeking in-person abortion in the United States.BMC health services research · 2026Article
- Demographic Factors Influencing Eligibility for EMA in South Australia.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Article
- Clinical Effectiveness and Cost-Effectiveness of Misoprostol in Comparison to Dilatation and Curettage for Treatment of First-Trimester Missed Abortion (Gestational Age ≤ 14 Weeks) in Iran.Health science reports · 2025Article
- Early Pregnancy Termination with Mifepristone and Misoprostol: Concurrent vs. 48-Hour Interval Administration in a Randomized Controlled Trial.Journal of clinical medicine · 2025Article
- Feasibility of medication abortion self-care service delivery in Ghana.Reproductive health · 2025Article
- Efficacy and Safety of a Regimen for Medical Abortion up to 63 Days of Gestation: A Retrospective Study in Northern Greece.Journal of clinical medicine · 2025Article
- Comprehensive Overview of Methods of Pregnancy Termination in Macaques and Marmosets.Veterinary sciences · 2024Review
- Medical treatment of miscarriage using misoprostol-a retrospective study.Archives of gynecology and obstetrics · 2024Article
- Article
- Exploring the Safety and Efficacy of Medical Termination of Pregnancy: A Comprehensive Review.Cureus · 2023Review
- A prospective, comparative study of clinical outcomes following clinic-based versus self-use of medical abortion.BMJ sexual & reproductive health · 2023Article
- Misoprostol-Induced Fever and Unnecessary Antibiotic Prescribing: A Retrospective Study.Infectious diseases and therapy · 2023Article
- Comparison of outpatient with inpatient mifepristone usage for cervical ripening: A randomised controlled trial.European journal of obstetrics & gynecology and reproductive biology: X · 2023Article
- Comparison of mifepristone plus misoprostol with misoprostol alone for first trimester medical abortion: A systematic review and meta-analysis.Frontiers in global women's health · 2023Review
- Comparison of the clinical efficacy of surgical versus medical method for first trimester pregnancy termination in Iran: A quasi-experimental research.Journal of education and health promotion · 2023Article
- Effect of misoprostol on type 3 transformation zone of the cervix among Cameroonian women.Gynecologic oncology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundA wide range of drugs have been studied for first trimester medical abortion. Studies evaluating different regimens, including combination mifepristone and misoprostol and misoprostol alone regimens, show varying results related to safety, efficacy and other outcomes. Thus, the objectives of this systematic review were to compare the safety, effectiveness and acceptability of medical abortion and to compare medical with surgical methods of abortion ≤63 days of gestation.
methodsPubmed and EMBASE were systematically searched from database inception through January 2019 using a combination of MeSH, keywords and text words. Randomized controlled trials on induced abortion at ≤63 days that compared different regimens of medical abortion using mifepristone and/or misoprostol and trials that compared medical with surgical methods of abortion were included. We extracted data into a pre-designed form, calculated effect estimates, and performed meta-analyses where possible. The primary outcomes were ongoing pregnancy and successful abortion.
resultsThirty-three studies composed of 22,275 participants were included in this review. Combined regimens using mifepristone and misoprostol had lower rates of ongoing pregnancy, higher rates of successful abortion and satisfaction compared to misoprostol only regimens. In combined regimens, misoprostol 800 μg was more effective than 400 μg. There was no significant difference in dosing intervals between mifepristone and misoprostol and routes of misoprostol administration in combination or misoprostol alone regimens. The rate of serious adverse events was generally low.
conclusionIn this systematic review, we find that medical methods of abortion utilizing combination mifepristone and misoprostol or misoprostol alone are effective, safe and acceptable. More robust studies evaluating both the different combination and misoprostol alone regimens are needed to strengthen existing evidence as well as assess patient perspectives towards a particular regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.